Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (245)	1/25/2000 11:32:00 PM
From: Miljenko Zuanic	Respond to of 523

Rick, <<He's also under intense pressure to repeat his '99 performance so that he can buy Croatia, rather than just visit, next time he feels like going home.>> Regardless that my '99 performance were close to 4X overall, I am optimistic that '00 will be better. NRGN will play important rule. Regards Tom's note on NRGN move and bts rally and discussed on many SI boards; So far we have random rally, where cancer, genomic and mAb have dominant rule. However, CNS field, as well as diabetes/obesity (in cardiovascular pharma holds majority cards, I think that you did mentioned this somewhere), have more oportunity/potential than any of two combination from this three field. Aged population factor. NBIX, NRGN, TTP, REGN, .. are my bets so far. Looking further. Going further, when rationale prevail exaburance, good comps will continue to rally while scam will be left as scam. Regardless of sector, as whole. CNS field will be next hot bt sector. NBIX move is only first step. Point is that recent NRGN move looks like delayed sympathy action. However, You know and I know that their business plans are solid as rocks, and only is a question of time when this will be translated in many new drug candidates. NRGN went after hard indications/targets. Mixed results. Gained experience count here. Investors and scientists did realize that there is more than simple surface approach of the brain chemistry. Brain science did progressed and knowledge is cumulative. At some point quantity will transform into quality. IMO, we are close to that point and NRGN is there to benefit and profit from it. Miljenko

To: scaram(o)uche who wrote (245)	1/29/2000 10:16:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 523

Neuroscience 2000;95(1):265-71 Distribution of galanin-1, -2 and -3 receptor messenger RNAs in central and peripheral rat tissues. Waters SM, Krause JE Department of Biochemistry and Molecular Biology, Neurogen Corporation, Branford, CT 06405, USA. [Medline record in process] Galanin is a neuropeptide widely expressed in the central nervous system and periphery. In rat, three galanin-binding receptors have been cloned and characterized. We report the qualitative and quantitative distribution of galanin-1, galanin-2, and galanin-3 messenger RNAs in central and peripheral rat tissues by reverse transcription-polymerase chain reaction and solution hybridization/RNase protection assays, respectively. Galanin-1 messenger RNA was detected exclusively in the central and peripheral nervous system with highest expression in hypothalamus, amygdala, spinal cord and dorsal root ganglia. Galanin-2 messenger RNA was highly expressed in hypothalamus, dorsal root ganglia, and kidney with moderate expression in several other tissues. Galanin-3 messenger RNA was widely distributed at low to moderate levels in many central and peripheral tissues. The observed expression of multiple galanin receptors in several tissues including hypothalamus, anterior pituitary and spinal cord supports earlier pharmacological studies suggesting the presence of more than one receptor subtype in these regions. The presence of multiple galanin receptors in these tissues in conjunction with the detection of a single subtype, galanin-2, in tissues such as heart and intestine, illustrates the potential complexity of galanin-associated actions in rat central nervous system and periphery.